China National Study of Adrenal Venous Sampling
CNAVS
A National Multicenter Study of Adrenal Venous Sampling for the Subtype Diagnosis of Primary Aldosteronism in China
1 other identifier
observational
1,500
1 country
48
Brief Summary
This multicenter study intends to combine retrospective analysis and prospective registry to evaluate the success rate and safety of adrenal venous sampling (AVS) via antecubital and femoral approach for patients with primary aldosteronism. The consistency of AVS with pathological results and clinical outcomes, the factors affecting the success of AVS, and the optimal population for AVS will be aslo analyzed in this study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2024
Typical duration for all trials
48 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 21, 2023
CompletedStudy Start
First participant enrolled
January 1, 2024
CompletedFirst Posted
Study publicly available on registry
January 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2026
January 9, 2024
January 1, 2024
3 years
December 21, 2023
January 5, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The success rate of bilateral adrenal venous sampling
Successful sampling will be defined by high selectivity index (cortisol in the adrenal vein/cortisol in inferior vena cava \>2 without ACTH simulation)
At AVS procedure
Secondary Outcomes (9)
The success rate of left adrenal venous sampling
At AVS procedure
The success rate of right adrenal venous sampling
At AVS procedure
Selection of intraoperative catheter
At AVS procedure
Time of the procedure
At AVS procedure
Time of fluoroscopy
At AVS procedure
- +4 more secondary outcomes
Study Arms (1)
Adrenal Venous Sampling
Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Interventions
Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Eligibility Criteria
Patients with confirmed primary aldosteronism aged from 18 to 65 with no limits in sex
You may qualify if:
- Aged from 18 to 65 with no limits in sex;
- Patients with confirmed primary aldosteronism;
- Patients or their legal representatives sign written informed consent approved by the ethics committee；
You may not qualify if:
- Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；
- An estimated glomerular filtration rate \<45 ml/min/1.73 m2, or serum creatinine \>176 μmol/L；
- Patients who refuse adrenalectomy;
- Suspected of having an adrenocortical carcinoma;
- Allergy to contrast agent;
- Pregnant, nursing, or planning to become pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (48)
Chuiyangliu Hospital affiliated to Tsinghua University
Beijing, Beijing Municipality, 100022, China
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100037, China
Beijing Luhe Hospital, Capital Medical University
Beijing, Beijing Municipality, 101100, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000, China
Chongqing General Hospital
Chongqing, Chongqing Municipality, 401147, China
People's Hospital Affiliated to ChongqingThree Gorges Medical college
Chongqing, Chongqing Municipality, 404100, China
Cardiovascular Hospital Xiamen University
Xiamen, Fujian, 361016, China
Lanzhou University Second Hospital
Lanzhou, Gansu, 730000, China
The Forth People's Hosptal of Nanhai District of Foshan City
Foshan, Guangdong, 528211, China
Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences)
Guangzhou, Guangdong, 510080, China
Shenzhen Third People's Hospital，Shenzhen, Guangdong Province 518112, China
Shenzhen, Guangdong, 518112, China
Shenzhen Dapeng New District Kuiyong People's Hospital
Shenzhen, Guangdong, 518116, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530000, China
Nanning Third People's Hospital
Nanning, Guangxi, 547000, China
The Second Affiliated Hospital Of Guizhou Medical University
Kaili, Guizhou, 556000, China
Tangshan hongci Hospital
Tangshan, Hebei, 063000, China
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150001, China
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, 450000, China
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
Zhengzhou Central Hospital Affiliated to Zhengzhou University
Zhengzhou, Henan, 450007, China
Zhengzhou Yihe Hospital
Zhengzhou, Henan, 450018, China
Zhoukou Central Hospital
Zhoukou, Henan, 466000, China
Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science
Xiangyang, Hubei, 441021, China
Yichang Central People's Hospital
Yichang, Hubei, 443000, China
Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
Jiangxi Provincial People's Hospital (The First Affiliated Hospital of Nanchang Medical College)
Nanchang, Jiangxi, 330038, China
Jilin Province FAW General ospital
Changchun, Jilin, 130051, China
Frist Aiffiliated Hospital of Dalian Medical University
Dalian, Liaoning, 116011, China
The First People's Hospital of Yinchuan
Yinchuan, Ningxia, 750000, China
Qinghai Province Cardiovascular and Cerebrovascular Disease Specialist Hospital
Xining, Qinghai, 810000, China
Xi'an People's Hospital
Xi'an, Shaanxi, 710018, China
Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China
Central Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, 250013, China
People's Hospital of Donga County, Shandong Province
Liaocheng, Shandong, 252200, China
Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
Shanghai Putuo District Central Hospital
Shanghai, Shanghai Municipality, 200062, China
The second hospital of Shanxi medical unversity
Taiyuan, Shanxi, 030001, China
The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, China
Chengdu, Sichuan, 610031, China
The First Affiliated Hospital of Chengdu Medical College
Chengdu, Sichuan, 610500, China
Chengdu Fifth People's Hospital
Chengdu, Sichuan, 611130, China
Tianjin Medical University General Hospital,
Tianjin, Tianjin Municipality, 300052, China
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, 300211, China
TEDA International Cardiovascular Hospital
Tianjin, Tianjin Municipality, 300457, China
Yili Kazak Autonomous Prefecture Friendship Hospital
Yili Kazak Autonomous Prefecture, Xinjiang, 835000, China
Fuwai Yunnan Cardiovascular Hospital
Kunming, Yunnan, 650102, China
Zhejiang Hospital
Hangzhou, Zhejiang, 310000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xiongjing Jiang, MD
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
December 21, 2023
First Posted
January 5, 2024
Study Start
January 1, 2024
Primary Completion (Estimated)
December 30, 2026
Study Completion (Estimated)
December 30, 2026
Last Updated
January 9, 2024
Record last verified: 2024-01